Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This research study evaluates the effects of an FDA-approved medication Gabapentin in individuals with Bipolar Disorder who smoke marijuana. Participants in the study will will be assigned to take either Gabapentin or a matched placebo. Study medication will be taken for 17 days. There will be 5 study visits, with 2 MRI brain imaging scans completed. Questionnaires and clinical interview measures will be completed at study visits along with consistent assessment of potential side effects from study medication.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
68 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Sara Hix
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal